Toray has created a new generation of dialyzers, the polysulphone (TS) UL series, and polymethylmethacrylate (PMMA) NF‐U series, which offer enhanced efficacy over the previous TS‐S series and NF‐H ...series. The aim of this study was to evaluate the safety and efficacy of these dialyzer series versus contrasted expanded hemodialysis (HDx) and postdilution hemodiafiltration (HDF). We conducted a prospective study in 12 patients. Each patient underwent six dialysis sessions: FX80 Cordiax in HD, Toraysulfone TS‐1.8 UL in HD, Theranova 400 in HDx, polymethylmethacrylate (PMMA) NF‐2.1 U in HDF, Toraysulfone TS‐2.1 UL in HDF, and FX80 Cordiax in HDF. The removal ratios (RRs) of urea, creatinine, ß2‐microglobulin, myoglobin, prolactin, α1‐microglobulin, α1‐acid glycoprotein, and albumin were compared intraindividually. Dialysate albumin loss was also measured. The RRs for β2‐microglobulin, myoglobin, prolactin, α1‐microglobulin, and α1‐acid glycoprotein were higher with the TS‐2.1 UL and FX80 Cordiax dialyzers in HDF than those obtained with HD treatments and NF‐2.1 U in HDF. The β2‐microglobulin, myoglobin, and prolactin RRs were also higher with HDx than those obtained with HD treatments. The myoglobin and prolactin RRs were higher with TS‐1.8 UL in HD than those obtained with helixone dialyzers in HD. Dialysate albumin loss was less than 3 g in all situations except in TS‐2.1 UL in HDF. The highest global removal score values were obtained with the TS‐2.1 UL and helixone dialyzers in HDF. Significant differences were found between all study situations. In conclusion, the new generation dialyzers, Toraysulfone TS Series UL and PMMA NF‐U series, show excellent behaviour and tolerance in HD and HDF, representing an upgrade versus their predecessor series. The higher permeability of the TS UL series has been proven with higher efficiency in HD and maximum performance in HDF. The new PMMA NF‐U series allows the use of HDF with good efficiency and complete safety.
The new generation of dialyzers, the Toraysulfone TS Series UL and PMMA NF‐U series, show excellent behavior and tolerance in HD and HDF.
The higher permeability of the TS Series UL has been proven with higher efficiency in HD and maximum performance in HDF.
The new PMMA NF‐U series allows it to be used in HDF with good efficiency and complete safety.
Introduction: The medium cut-off Elisio HX dialyzer by Nipro became commercially available in Europe in 2021, but there are still no reports of in vivo data. This study aimed to evaluate the safety ...and efficacy of it compared with previously evaluated hemodialysis (HD), expanded HD (HDx), and postdilution hemodiafiltration (HDF) treatments. Methods: A prospective study was carried out on 18 patients who underwent 5 dialysis sessions: FX80 Cordiax in HD, Elisio H19 in HD, Elisio HX19 in HDx, Theranova 400 in HDx, and FX80 Cordiax in HDF. The reduction ratios of urea, creatinine, ß 2 -microglobulin, myoglobin, kappa FLC, prolactin, α 1 -microglobulin, α 1 -acid glycoprotein, lambda FLC, and albumin were compared. Dialysate albumin loss was measured. Results: The comparison between the different dialysis modalities revealed no difference for small molecules, but HDx and HDF were significantly more efficient than HD for medium and large molecule removal. The efficacy of Elisio HX19 dialyzer in HDx was similar to the Theranova 400, superior to both dialyzers in HD, and slightly lower than HDF. Albumin losses in dialysate with HD dialyzers were less than 1 g, but between 1.5 and 2.5 g in HDx and HDF. The global removal score (GRS) values with HDx treatments were statistically significantly higher than those with HD. The highest GRS was obtained with the helixone dialyzer in HDF. Conclusions: The new MCO dialyzer, Elisio HX, performs with excellent behavior and tolerance. It represents an upgrade compared to their predecessor and is very close to the removal capacity of HDF treatment.
The aim of this study was to analyze the differences between vancomycin clearance (Kd) with high‐flux hemodialysis (HFHD) and on‐line hemodiafiltration (OL‐HDF). The OL‐HDF therapy combined the ...diffusion and convective transport of solutes. To compare the Kd, a vancomycin loading dose of 1 g was administered intravenously post‐dialysis to 11 chronic and anuric (<100 mL/24 h) hemodialysis patients, undergoing HFHD and post‐dilutional OL‐HDF in consecutive therapies. Additional doses of 0.5 g were administered after 45 minutes at the end of each dialysis therapy during antibiotic treatment. Blood samples were drawn from arterial and venous lines at the start of hemodialysis sessions and at the first, second, third, and fourth hours. Additional samples were drawn at 15, 30, and 45 minutes after the end of dialysis therapy. Vancomycin plasma concentration, blood urea nitrogen (BUN), creatinine, and β2‐microglobulin were measured. The patients’ hydration status was evaluated by bioimpedance analysis. The mean of vancomycin dialyzer clearance (Kddc) calculated was 110.8 ± 15 mL/min with HFHD and 146.8 ± 13.8 mL/min with OL‐HDF (P = 0.025). Significant differences were also obtained for β2‐microglobulin clearance, Kddc 72.6 ± 15.4 mL/min with HFHD and 113.4 ± 24.2 mL/min with OL‐HDF (P = 0.012), whereas no differences were found for BUN or creatinine. Additionally, to analyze differences between HFHD and OL‐HDF, a variable volume dual pool mathematical model was developed to estimate the body clearance (Kdbc), extraction mass (Me), and inter‐compartment mass‐transfer coefficient (K12) of each molecule. A higher vancomycin Kddc with OL‐HDF produced by convection improved removal of antibiotic; this can compromise achieving a therapeutic concentration target. We recommended evaluating increased loading doses of vancomycin and avoiding administration during OL‐HDF to assure adequate treatment.
The aim of this work was to study the association of potential biomarkers with fast aortic stenosis (AS) progression. Patients with moderate-to-severe AS were classified as very fast progressors ...(VFP) if exhibited an annualized change in peak velocity (aΔVmax) ≥0.45m/s/year and/or in aortic valve area (aΔAVA) ≥−0.2cm2/year. Respective cut-off values of ≥0.3m/s/year and ≥−0.1cm
2
/year defined fast progressors (FP), whereas the remaining patients were non-fast progressors (non-FP). Baseline markers of lipid metabolism, inflammation, and cardiac overload were determined. Two hundred and nine patients (97 non-FP, 38 FP, and 74 VFP) were included. PCSK9 levels were significantly associated with VFP (OR 1.014 95%CI 1.005-1.024, for every 10 ng/mL), as were active smoking (OR 3.48) and body mass index (BMI, OR 1.09), with an AUC of 0.704 for the model. PCSK9 levels, active smoking, and BMI were associated with very fast AS progression in our series, suggesting that inflammation and calcification participate in disease progression.
La hemodiafiltración on-line (HDF-OL) es actualmente la técnica más efectiva. Varios estudios aleatorizados y metaanálisis han observado una reducción de la mortalidad, con una asociación en relación ...directa con el volumen convectivo. En el momento presente no está bien establecido si el aumento del flujo del líquido de diálisis (Qd) puede suponer mejores resultados en términos de eficacia convectiva y depurativa. El objetivo del estudio fue valorar, en pacientes en tratamiento con HDF-OL, el efecto de la variación del Qd sobre el volumen convectivo y su capacidad depurativa.
Se incluyeron 59 pacientes, 45 varones y 14 mujeres que se encontraban en programa de HDF-OL con monitor 5008 Cordiax con autosustitución. Cada paciente fue analizado en 5 sesiones con HDF-OL posdilucional, con dializadores de helixona, en las que solo se varió el Qd (300, 400, 500, 600 y 700ml/min). En cada sesión se determinaron concentración de urea (60Da), creatinina (113 Da), β2-microglobulina (11.800Da), mioglobina (17.200Da) y α1-microglobulina (33.000Da) en suero al inicio y al final de cada sesión, para calcular el porcentaje de reducción de estos solutos.
Se objetivó un aumento de litros de Qd por sesión, desde 117,9±6,4 L con Qd de 300ml/min hasta 232,4±12 L con Qd 700ml/min. No se determinaron cambios en el volumen de sustitución ni en el volumen convectivo. En términos de difusión, el incremento del Qd mostró un aumento significativo de la dosis de diálisis, con un aumento de Kt de 68±6,9 L con Qd 300ml/min hasta 75,5±7,3 L con Qd 700ml/min (p<0,001), y un aumento progresivo del porcentaje de reducción de urea con el incremento del Qd, que era significativamente inferior con Qd 300ml/min. No se objetivaron cambios en el resto de moléculas estudiadas.
La variación del Qd en HDF-OL no modifica el volumen convectivo. Un mayor Qd mostró un discreto incremento de la depuración de la urea, sin variaciones en las medianas ni en las grandes moléculas. Es recomendable optimizar el Qd al mínimo posible que garantice una adecuada dosis de diálisis y permita racionalizar el consumo de agua y concentrado de diálisis.
Currently, on-line hemodiafiltration (HDF-OL) is the most effective technique. Several randomized studies and meta-analyses have shown a reduced mortality and a direct association with convective volume has been reported. At present, it has not been established if an increased dialysate flow (Qd) results in improved results in terms of convective and depurative efficiency. We aim at assessing the effects of Qd variations on convective volume and its depurative capacity in patients on HDF-OL.
A total of 59 patients (45 men and 14 women) from a HDF-OL programme in which a monitor 5008 Cordiax with self-replacement was used, were enrolled. Patients were assessed in 5 sessions with post-dilutional HDF-OL, using helixone-based dialyzers, with only Qd being changed (300, 400, 500, 600 and 700ml/min). Serum levels of urea (60Da), creatinine (113 Da), β2-microglobulin (11,800Da), myoglobin (17,200Da) and α1-microglobulin (33,000Da) were measured at the beginning and at the end of each session, in order to estimate the percent reduction of such solutes.
An increased dialysate volume per session was observed, from 117.9±6.4 L with Qd 300ml/min to 232.4±12 L with Qd 700ml/min. No changes were found in replacement volume or convective volume. Regarding diffusion, Qd increase was associated to a significantly increased dialysis dose, with an increased Kt from 68±6.9 L with Qd 300ml/min to 75.5±7.3 L with Qd 700ml/min (p<0,001), and a gradually increased percent reduction in urea associated to increased Qd with significantly lower levels being found with Qd 300ml/min. No changes were found in other measured substances.
Qd variations in HDF-OL do not change convective volume. A higher Qd was associated to a slightly increased urea clearance with no change being observed for medium and large molecules. Qd optimisation to the minimal level assuring an adequate dialysis dose and allowing water and dialysate use to be rationalised should be recommended.
Introducción: El incremento en la inclusión de personas de edad avanzada a los programas de hemodiálisis se relaciona con un aumento de la prevalencia de fragilidad, considerada predictora de ...discapacidad y asociada a eventos adversos de salud. Dado su carácter reversible, es importante hacer un cribaje para mejorar la práctica clínica.
Objetivo: Evaluar el grado de fragilidad y estado funcional del paciente en nuestra unidad de hemodiálisis y analizar las diferencias entre diabéticos y no diabéticos.
Material y Método: Estudio observacional de corte transversal. La fragilidad se midió utilizando el fenotipo de Fried y la valoración funcional mediante las escalas Barthel, Lawton, Downton y la Short Physical Performance Battery. Se evaluó comorbilidad y riesgo de caídas con las escalas Charlson y Downton respectivamente. Se comparó entre grupos de diabéticos y no diabéticos y se analizó la relación entre la fragilidad y la edad, dependencia, comorbilidad y riesgo de caídas.
Resultados: Se incluyeron 128 pacientes. El 45% tenían Diabetes. Los pacientes con diabetes tenían una edad media mayor que los no diabéticos (74,2±11 vs 67,8±15 años) y mayor comorbilidad (Charlson 8,2±2,2 vs 5,8±2,4). El 25% de los pacientes presentaron fragilidad, observando una tendencia que sugirió mayor fragilidad, peor capacidad funcional y mayor grado de dependencia en los pacientes diabéticos, aunque de forma no significativa.
Conclusiones: Una cuarta parte de la población estudiada presenta fragilidad, con una tendencia más acusada a padecerla los pacientes diabéticos, que podría estar relacionada con mayor edad, mayor comorbilidad y menor capacidad funcional que los no diabéticos.
PDF
